Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
December 13, 2021 16:01 ET
|
Sensei Biotherapeutics
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
November 19, 2021 16:02 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 12, 2021 07:02 ET
|
Sensei Biotherapeutics
V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein that has been recognized as an important potential immunotherapeutic target Preclinical data...
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
November 09, 2021 08:54 ET
|
Sensei Biotherapeutics
- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer’s...
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
November 03, 2021 09:01 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 01, 2021 08:05 ET
|
Sensei Biotherapeutics
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
August 04, 2021 07:45 ET
|
Sensei Biotherapeutics
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company...
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
August 02, 2021 08:01 ET
|
Sensei Biotherapeutics
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
June 28, 2021 16:05 ET
|
Sensei Biotherapeutics
- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs - - Discontinuation of first-generation,...
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
May 19, 2021 17:03 ET
|
Sensei Biotherapeutics
– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated – – One deep (71% tumor reduction) and durable (11 months) partial response and two longstanding (8 and 10...